Javascript must be enabled to continue!
How to Improve Cancer Patients ENrollment in Clinical Trials From rEal-Life Databases Using the Observational Medical Outcomes Partnership Oncology Extension: Results of the PENELOPE Initiative in Urologic Cancers
View through CrossRef
PURPOSE To compare the computability of Observational Medical Outcomes Partnership (OMOP)–based queries related to prescreening of patients using two versions of the OMOP common data model (CDM; v5.3 and v5.4) and to assess the performance of the Greater Paris University Hospital (APHP) prescreening tool. MATERIALS AND METHODS We identified the prescreening information items being relevant for prescreening of patients with cancer. We randomly selected 15 academic and industry-sponsored urology phase I-IV clinical trials (CTs) launched at APHP between 2016 and 2021. The computability of the related prescreening criteria (PC) was defined by their translation rate in OMOP-compliant queries and by their execution rate on the APHP clinical data warehouse (CDW) containing data of 205,977 patients with cancer. The overall performance of the prescreening tool was assessed by the rate of true- and false-positive cases of three randomly selected CTs. RESULTS We defined a list of 15 minimal information items being relevant for patients' prescreening. We identified 83 PC of the 534 eligibility criteria from the 15 CTs. We translated 33 and 62 PC in queries on the basis of OMOP CDM v5.3 and v5.4, respectively (translation rates of 40% and 75%, respectively). Of the 33 PC translated in the v5.3 of the OMOP CDM, 19 could be executed on the APHP CDW (execution rate of 58%). Of 83 PC, the computability rate on the APHP CDW reached 23%. On the basis of three CTs, we identified 17, 32, and 63 patients as being potentially eligible for inclusion in those CTs, resulting in positive predictive values of 53%, 41%, and 21%, respectively. CONCLUSION We showed that PC could be formalized according to the OMOP CDM and that the oncology extension increased their translation rate through better representation of cancer natural history.
American Society of Clinical Oncology (ASCO)
Title: How to Improve Cancer Patients ENrollment in Clinical Trials From rEal-Life Databases Using the Observational Medical Outcomes Partnership Oncology Extension: Results of the PENELOPE Initiative in Urologic Cancers
Description:
PURPOSE To compare the computability of Observational Medical Outcomes Partnership (OMOP)–based queries related to prescreening of patients using two versions of the OMOP common data model (CDM; v5.
3 and v5.
4) and to assess the performance of the Greater Paris University Hospital (APHP) prescreening tool.
MATERIALS AND METHODS We identified the prescreening information items being relevant for prescreening of patients with cancer.
We randomly selected 15 academic and industry-sponsored urology phase I-IV clinical trials (CTs) launched at APHP between 2016 and 2021.
The computability of the related prescreening criteria (PC) was defined by their translation rate in OMOP-compliant queries and by their execution rate on the APHP clinical data warehouse (CDW) containing data of 205,977 patients with cancer.
The overall performance of the prescreening tool was assessed by the rate of true- and false-positive cases of three randomly selected CTs.
RESULTS We defined a list of 15 minimal information items being relevant for patients' prescreening.
We identified 83 PC of the 534 eligibility criteria from the 15 CTs.
We translated 33 and 62 PC in queries on the basis of OMOP CDM v5.
3 and v5.
4, respectively (translation rates of 40% and 75%, respectively).
Of the 33 PC translated in the v5.
3 of the OMOP CDM, 19 could be executed on the APHP CDW (execution rate of 58%).
Of 83 PC, the computability rate on the APHP CDW reached 23%.
On the basis of three CTs, we identified 17, 32, and 63 patients as being potentially eligible for inclusion in those CTs, resulting in positive predictive values of 53%, 41%, and 21%, respectively.
CONCLUSION We showed that PC could be formalized according to the OMOP CDM and that the oncology extension increased their translation rate through better representation of cancer natural history.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Interview: Timothy Clinton
Interview: Timothy Clinton
What has driven you to specialise in urologic oncology, in particular the management of advanced testicular and bladder malignancies?
My interest in urology started in medical scho...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Accuracy of medical oncology prognosis for patients with metastatic cancer evaluated for enrollment onto an ongoing randomized clinical trial.
Accuracy of medical oncology prognosis for patients with metastatic cancer evaluated for enrollment onto an ongoing randomized clinical trial.
12063 Background: For patients with metastatic cancer, a key aspect of interdisciplinary care has involved the overall prognosis provided by Medical Oncology, which often dictates...
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
Purpose: This article reviews the essential clinical trials that have led to these immunotherapy approvals and explores the use of predictive biomarkers, such as PD-L1 expression a...
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
ABSTRACT
Background
Research infra-structure is essential for conducting phase III cancer clinical trials as its lack precludes...
Pedagogical partnership in higher education institutions: expediency and capabilities
Pedagogical partnership in higher education institutions: expediency and capabilities
The article deals with the issues related to pedagogical partnership in higher education institutions. The author analyses its essence, the reason for its popularity in a number of...

